nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—Cytosolic sensors of pathogen-associated DNA—MB21D1—conduct disorder	0.0636	0.0636	CbGpPWpGaD
Thalidomide—NFKB1—Cytosolic sensors of pathogen-associated DNA—POLR3A—conduct disorder	0.0467	0.0467	CbGpPWpGaD
Thalidomide—NFKB1—Melatonin metabolism and effects—MAOA—conduct disorder	0.0424	0.0424	CbGpPWpGaD
Thalidomide—NFKB1—Oxidative Stress—MAOA—conduct disorder	0.0413	0.0413	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—CGA—conduct disorder	0.0412	0.0412	CbGpPWpGaD
Thalidomide—TNF—Monoamine Transport—SLC6A4—conduct disorder	0.0397	0.0397	CbGpPWpGaD
Thalidomide—CYP1A2—Methylation—COMT—conduct disorder	0.0267	0.0267	CbGpPWpGaD
Thalidomide—CYP1A1—Estrogen metabolism—COMT—conduct disorder	0.0262	0.0262	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0194	0.0194	CbGpPWpGaD
Thalidomide—CYP1A1—Melatonin metabolism and effects—MAOA—conduct disorder	0.0177	0.0177	CbGpPWpGaD
Thalidomide—CYP1A1—Oxidative Stress—MAOA—conduct disorder	0.0173	0.0173	CbGpPWpGaD
Thalidomide—NFKB1—Initiation of transcription and translation elongation at the HIV-1 LTR—EP300—conduct disorder	0.0169	0.0169	CbGpPWpGaD
Thalidomide—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.0167	0.0167	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.0147	0.0147	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—MAOA—conduct disorder	0.0145	0.0145	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.0127	0.0127	CbGpPWpGaD
Thalidomide—PTGS1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0114	0.0114	CbGpPWpGaD
Thalidomide—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.0113	0.0113	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MB21D1—conduct disorder	0.0112	0.0112	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.0112	0.0112	CbGpPWpGaD
Thalidomide—NFKB1—IL-4 Signaling Pathway—EP300—conduct disorder	0.0111	0.0111	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—EP300—conduct disorder	0.0111	0.0111	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.011	0.011	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MB21D1—conduct disorder	0.0107	0.0107	CbGpPWpGaD
Thalidomide—NFKB1—Notch Signaling Pathway—EP300—conduct disorder	0.0101	0.0101	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00965	0.00965	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00965	0.00965	CbGpPWpGaD
Thalidomide—NFKB1—Cytosolic sensors of pathogen-associated DNA—EP300—conduct disorder	0.00949	0.00949	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—EP300—conduct disorder	0.00905	0.00905	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.009	0.009	CbGpPWpGaD
Thalidomide—CYP2E1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00853	0.00853	CbGpPWpGaD
Thalidomide—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00851	0.00851	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—EP300—conduct disorder	0.00849	0.00849	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00841	0.00841	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—EP300—conduct disorder	0.00839	0.00839	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—POLR3A—conduct disorder	0.00824	0.00824	CbGpPWpGaD
Thalidomide—NFKB1—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—EP300—conduct disorder	0.00814	0.00814	CbGpPWpGaD
Thalidomide—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00804	0.00804	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—EP300—conduct disorder	0.00798	0.00798	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—POLR3A—conduct disorder	0.00782	0.00782	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.00757	0.00757	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—WASF1—conduct disorder	0.00693	0.00693	CbGpPWpGaD
Thalidomide—TNF—Signaling events mediated by HDAC Class I—EP300—conduct disorder	0.0069	0.0069	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00686	0.00686	CbGpPWpGaD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00658	0.00658	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—WASF1—conduct disorder	0.00658	0.00658	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MB21D1—conduct disorder	0.00654	0.00654	CbGpPWpGaD
Thalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—EP300—conduct disorder	0.00639	0.00639	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MB21D1—conduct disorder	0.0062	0.0062	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—COMT—conduct disorder	0.00611	0.00611	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—MAOA—conduct disorder	0.00606	0.00606	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.006	0.006	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00597	0.00597	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.0053	0.0053	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.0053	0.0053	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00519	0.00519	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00513	0.00513	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.0049	0.0049	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—POLR3A—conduct disorder	0.0048	0.0048	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00477	0.00477	CbGpPWpGaD
Thalidomide—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.00469	0.00469	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—COMT—conduct disorder	0.00456	0.00456	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—COMT—conduct disorder	0.00455	0.00455	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—POLR3A—conduct disorder	0.00455	0.00455	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—MAOA—conduct disorder	0.00453	0.00453	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.00452	0.00452	CbGpPWpGaD
Thalidomide—CYP2E1—Metapathway biotransformation—COMT—conduct disorder	0.0045	0.0045	CbGpPWpGaD
Thalidomide—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.00449	0.00449	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—COMT—conduct disorder	0.0043	0.0043	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—MAOA—conduct disorder	0.00427	0.00427	CbGpPWpGaD
Thalidomide—CYP1A1—Metapathway biotransformation—COMT—conduct disorder	0.00424	0.00424	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00412	0.00412	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00406	0.00406	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—WASF1—conduct disorder	0.00404	0.00404	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—WASF1—conduct disorder	0.00383	0.00383	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—EP300—conduct disorder	0.00369	0.00369	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00366	0.00366	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00363	0.00363	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—COMT—conduct disorder	0.00352	0.00352	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—MAOA—conduct disorder	0.0035	0.0035	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—COMT—conduct disorder	0.00347	0.00347	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00338	0.00338	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00338	0.00338	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CGA—conduct disorder	0.00326	0.00326	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—COMT—conduct disorder	0.00321	0.00321	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—MAOA—conduct disorder	0.00319	0.00319	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	0.00317	0.00317	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—EP300—conduct disorder	0.00313	0.00313	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CGA—conduct disorder	0.00309	0.00309	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00309	0.00309	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00299	0.00299	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—COMT—conduct disorder	0.00274	0.00274	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00273	0.00273	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.00272	0.00272	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.0027	0.0027	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—EP300—conduct disorder	0.00264	0.00264	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—WASF1—conduct disorder	0.00261	0.00261	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—conduct disorder	0.00258	0.00258	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—WASF1—conduct disorder	0.00248	0.00248	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00233	0.00233	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CGA—conduct disorder	0.00231	0.00231	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00191	0.00191	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EP300—conduct disorder	0.0019	0.0019	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CGA—conduct disorder	0.00184	0.00184	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DRD4—conduct disorder	0.00182	0.00182	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—conduct disorder	0.00178	0.00178	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DRD4—conduct disorder	0.00173	0.00173	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CGA—conduct disorder	0.00173	0.00173	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CGA—conduct disorder	0.00172	0.00172	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EP300—conduct disorder	0.00167	0.00167	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CGA—conduct disorder	0.00163	0.00163	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EP300—conduct disorder	0.00159	0.00159	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EP300—conduct disorder	0.00144	0.00144	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CGA—conduct disorder	0.00133	0.00133	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CGA—conduct disorder	0.00122	0.00122	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—conduct disorder	0.00119	0.00119	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—conduct disorder	0.00113	0.00113	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—COMT—conduct disorder	0.00104	0.00104	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CGA—conduct disorder	0.00104	0.00104	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MAOA—conduct disorder	0.00104	0.00104	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00101	0.00101	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EP300—conduct disorder	0.000976	0.000976	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EP300—conduct disorder	0.000926	0.000926	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EP300—conduct disorder	0.000855	0.000855	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—COMT—conduct disorder	0.000829	0.000829	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MAOA—conduct disorder	0.000823	0.000823	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000798	0.000798	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—COMT—conduct disorder	0.00078	0.00078	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—COMT—conduct disorder	0.000779	0.000779	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MAOA—conduct disorder	0.000775	0.000775	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MAOA—conduct disorder	0.000773	0.000773	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—COMT—conduct disorder	0.000736	0.000736	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MAOA—conduct disorder	0.00073	0.00073	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000708	0.000708	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—conduct disorder	0.000631	0.000631	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—COMT—conduct disorder	0.000602	0.000602	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—conduct disorder	0.000598	0.000598	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MAOA—conduct disorder	0.000598	0.000598	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00058	0.00058	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—COMT—conduct disorder	0.000549	0.000549	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MAOA—conduct disorder	0.000545	0.000545	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000529	0.000529	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—COMT—conduct disorder	0.000469	0.000469	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MAOA—conduct disorder	0.000466	0.000466	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000452	0.000452	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—conduct disorder	0.000448	0.000448	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—conduct disorder	0.000424	0.000424	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—conduct disorder	0.000355	0.000355	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—conduct disorder	0.000335	0.000335	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—conduct disorder	0.000334	0.000334	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—conduct disorder	0.000315	0.000315	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—conduct disorder	0.000258	0.000258	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—conduct disorder	0.000235	0.000235	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—conduct disorder	0.000201	0.000201	CbGpPWpGaD
